Plant Name: Convallaria majalis
Taxonomic Information:
Plant ID: NPO157
Plant Latin Name: Convallaria majalis
Taxonomy Genus: Convallaria
Taxonomy Family: Asparagaceae
Plant External Links:
NCBI TaxonomyDB:
32189
Plant-of-the-World-Online:
533487-1
Used in Medicines:
Country/Region:
India; LithuaniaTraditional Medicine System:
Indian Folk; HomeopathyMedicinal Functions:
Antianxiety; Antiarrhythmic; Anticonvulsant; Antispasmodic; Cardiotonic; Diuretic; Emetic; Febrifuge; Laxative; Poultice; Sedative
Geographical Distribution:
Canada; Turkey; Italy; Lithuania; France; Norway; Belarus; Germany; Belgium; Kazakhstan; Spain; Ukraine; Netherlands; Denmark; Poland; Finland; United States; Sweden; Switzerland; Russia; Bulgaria; Romania; Albania; India; United Kingdom; Austria; Greece; Hungary
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| BLM; AOX1; | |
| EGFR; | |
| CA2; CA7; CA12; | |
| ESR2; ESR1; | |
| ESRRB; ESRRA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.576E-08 | 3.540E-04 | CYP1A1, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 9.070E-08 | 3.950E-04 | BLM, CA12, CA2, CA7, ESR1, ESR2, ESRRA, ESRRB |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.109E-07 | 5.740E-04 | CA12, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.146E-07 | 1.273E-03 | CYP1A1, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 6.399E-07 | 1.273E-03 | ESR1, ESR2, ESRRA, ESRRB |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 6.433E-07 | 1.273E-03 | ESR1, ESR2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.929E-06 | 3.000E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.274E-06 | 4.289E-03 | CA12, CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 3.348E-06 | 4.289E-03 | ESR1, ESR2, ESRRA, ESRRB |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.856E-06 | 4.419E-03 | ESR1, ESR2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.049E-06 | 6.320E-03 | CA12, CA2, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.478E-06 | 6.320E-03 | CYP1A1, CYP1B1, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 7.134E-06 | 6.395E-03 | BLM, CYP1A1, CYP1B1, EGFR, ESR1 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 7.636E-06 | 6.395E-03 | ESR1, ESR2, ESRRA, ESRRB |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.636E-06 | 6.395E-03 | AOX1, CYP1A1, CYP1B1, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.088E-05 | 8.463E-03 | ESR1, ESR2, ESRRA, ESRRB |
| MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 1.348E-05 | 9.466E-03 | EGFR, ESR1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.076E-06 | 1.365E-04 | CYP1A1, AOX1, CYP1B1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.837E-07 | 1.901E-05 | CA12, CA2, CA7 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.780E-05 | 3.976E-04 | CYP2C9, CYP1A1, AOX1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.525E-05 | 4.229E-04 | CYP2C9, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 6.287E-05 | 7.021E-04 | ESR1, EGFR, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.579E-05 | 4.796E-04 | CYP2C9, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 7.188E-04 | 6.880E-03 | CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.484E-03 | 9.946E-03 | ESR1, ESR2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.364E-03 | 9.946E-03 | CYP2C9, AOX1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 9.663E-04 | 8.093E-03 | CYP1A1, CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; EGFR; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | EGFR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; EGFR; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; EGFR; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
